Biolytx is an emerging drug development company confronting the crisis in antibiotic (AB) drug resistance through the advancement of a suite of antimicrobial peptide drug candidates for the treatment of serious pathogens with no current therapeutic options.
Our core technology is the development of a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.
April 26, 2016 – Excerpt from NewsOk: “Through an association with William Hagstrom of Alpha Bio Partners, Branch became acquainted with OU professor Anne Pereira,…Read More
December 16, 2015 – Excerpt from OCRID: University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of…Read More
March 25 , 2015 – Excerpt from: Oklahoma JustGoodNews.Biz OKLAHOMA CITY — In 2004, i2E launched a “Meet the Scientist” speaker series in which Oklahoma researchers…Read More